I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-2. (Cancelled)

Claim 3. (Previously presented) A drug packaging system comprising combined prescription drug therapy comprising:

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof;

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof; and

packaging material comprising a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of naproxen or a pharmaceutically acceptable salt thereof.

Claims 4-5. (Cancelled)

Claim 6. (Previously presented) The drug packaging system of claim 3, wherein each unit dosage form is independently selected from the group consisting of a tablet, capsule, gel cap, and a caplet.

Claims 7-15. (Cancelled)

Claim 16. (Previously presented) The drug packaging system of claim 3 wherein said system comprises unit doses for up to 28 days.

Claim 17. (Previously presented) The drug packaging system of claim 3 wherein said system comprises unit doses for 7-14 days.

Claim 18. (Cancelled)

Claim 19. (Currently Amended) A method of treating a disease or condition comprising:

(a) arranging

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; into

a blister package comprising:

(i) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of lansoprazole or pharmaceutically acceptable salt thereof, and

(ii) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of naproxen or a pharmaceutically acceptable salt thereof;

to form a drug packaging system;

(b) rupturing one or more substrates to dispense one or more unit doses from the drug packaging system; and

(c) administering said one or more dispensed dosage forms to a human patient according to indicia included in said packaging system, said indicia providing dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof~~; and~~.

Claim 20. (Original) The method of claim 19 which provides therapy for 1-28 days.

Claim 21. (Cancelled)

Claim 22. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof are capsules.

Claim 23. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof are tablets.

Claim 24. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole comprise 15 mg lansoprazole.

Claim 25. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen comprise 500 mg naproxen.

Claim 26. (Cancelled)

Claim 27. (Previously presented) The drug packaging system of claim 3, wherein the indicia is located on the unit dosage forms.

Claim 28. (Previously presented) The drug packaging system of claim 3, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

Claim 29. (Previously presented) The drug packaging system of claim 3, wherein one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof is suitable for once daily dosing.

Claim 30. (Previously presented) The drug packaging system of claim 3, further comprising indicia that provides information to aid with removal of the unit dosage forms.

Claim 31. (Previously presented) The drug packaging system of claim 30, wherein the indicia is located on the unit dosage forms.

Claim 32. (Previously presented) The drug packaging system of claim 30, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

Claim 33. (Previously presented) A drug packaging system comprising combined prescription drug therapy comprising

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof and

unit dosage forms containing an NSAID or a pharmaceutically acceptable salt thereof;

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and NSAID or pharmaceutically acceptable salt thereof; and

packaging material comprising a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of said NSAID or pharmaceutically acceptable salt thereof.

Claim 34. (Previously presented) The drug packaging system of claim 3, wherein the indicia is located on the packaging material.

Claim 35. (Previously presented) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of lansiprazole or a pharmaceutically acceptable salt thereof and one or more unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; and

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof.